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increase in fasting serum triglyceride levels in nondiabetic 
individuals during 5 years of follow-up. This effect of the 
wGRS is accentuated by increasing insulin resistance.—
Justesen, J. M., E. A. Andersson, K. H. Allin, C. H. Sandholt, 
T. Jørgensen, A. Linneberg, M. E. Jørgensen, T. Hansen, 
O. Pedersen, and N. Grarup. Increasing insulin resistance 
accentuates the effect of triglyceride-associated loci on 
serum triglycerides during 5 years. J. Lipid Res. 2016. 57: 
2193–2199.
Supplementary key words  genetic  association  •  genetic  risk  score  • 
interaction
A high level of circulating triglycerides is a risk factor for 
type 2 diabetes, myocardial infarction, ischemic heart dis-
ease, and all-cause mortality (1–4). A recent Mendelian 
randomization study supports a causal effect of triglycer-
ides on coronary heart disease risk (5). Regulation of blood 
levels of triglycerides involves a complex interplay implicat-
ing both the liver and pancreas. Some of the important 
players in this regard are body adiposity, insulin resistance, 
and glucose homeostasis (6). In addition, circulating tri-
glyceride levels are heritable, as shown in a recent popula-
tion-based study of twins (H2 = 0.59; h2 = 0.33) (7). Genetic 
association studies have identified more than 40 SNPs 
Abstract Blood concentrations of triglycerides are influ-
enced by genetic factors as well as a number of environmen-
tal factors, including adiposity and glucose homeostasis. The 
aim was to investigate the association between a serum tri-
glyceride weighted genetic risk score (wGRS) and changes in 
fasting serum triglyceride level over 5 years and to test 
whether the effect of the wGRS was modified by 5 year 
changes of adiposity, insulin resistance, and lifestyle factors. 
A total of 3,474 nondiabetic individuals from the Danish In-
ter99 cohort participated in both the baseline and 5 year 
follow-up physical examinations and had information on the 
wGRS comprising 39 genetic variants. In a linear regression 
model adjusted for age, sex, and baseline serum triglycer-
ide, the wGRS was associated with increased serum triglycer-
ide levels over 5 years [per allele effect = 1.3% (1.0–1.6%); 
P = 1.0 × 1017]. This triglyceride-increasing effect of the 
wGRS interacted with changes in insulin resistance (Pinteraction = 
1.5 × 106). This interaction indicated that the effect of the 
wGRS was stronger in individuals who became more insulin 
resistant over 5 years.  In conclusion, our findings suggest 
that increased genetic risk load is associated with a larger 
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by changes in adiposity, insulin resistance, or the lifestyle 
factors  (physical  activity,  dietary  habits,  smoking  habits, 
and alcohol intake).
MATERIALS AND METHODS
Inter99 study population
The Inter99 study (clinicaltrials.gov identification number: 
NCT00289237) is a population-based nonpharmacological inter-
vention  study  for  ischemic  heart  disease  conducted  at  the  Re-
search Centre for Prevention and Health in Glostrup, Denmark 
(https://www.regionh.dk/rcph/population-based-epidemiology/ 
Pages/The-Inter99-Study.aspx) (20). A random sample of 13,016 
individuals living in Copenhagen County (aged 30–60 years) was 
drawn  from  the  Civil  Registration  System,  and  further  preran-
domized into high-intensity (90%) and low-intensity (10%) inter-
vention groups. The baseline health examination was attended by 
6,784 (52%) (median age 45 years). All participants received indi-
vidual lifestyle counseling at the baseline examination, focused on 
habits of smoking, physical activity, diet, and use of alcohol. The 
high intensity group was, in addition, offered group-based life-
style counseling if they were considered at high risk for ischemic 
heart  disease.  Follow-up  examinations  were  conducted  after  5 
years with a participation rate of 66% (n = 4,511) (21, 22). This 
intervention program was of rather low intensity with examina-
tions and individual tailored lifestyle counseling up to four times 
over 5 years. Those at high risk of ischemic heart disease based on 
predefined criteria were, in addition, offered six sessions of 
group-based lifestyle counseling. The intervention had no effect 
on primary and secondary endpoints: ischemic heart disease, 
stroke, and all-cause mortality after 10 years (23).
A total of 3,474 individuals had information on the wGRS and 
fasting serum triglyceride levels at baseline and follow-up. De-
scriptions of study participants are shown in supplemental Table 
S1. All participants were Danes by self-report. Written informed 
consent was obtained from all participants and the study was ap-
proved by the Scientific Ethics Committee of the Capital Region 
of Denmark (Inter99: KA98155) and was in accordance with the 
principles of the Declaration of Helsinki II.
Biochemical and anthropometric measures
At the baseline and 5 year follow-up health examination, body 
weight  (in kilograms)  and height  (to  the nearest  0.5  cm) were 
measured in light indoor clothing and without shoes. BMI was 
defined as body weight in kilograms divided by height in meters 
squared (kg/m2). Blood samples were drawn in the morning after 
a 12 h overnight fast. All participants without previously diag-
nosed diabetes were characterized by a standardized 75 g oral glu-
cose tolerance test (OGTT) with plasma glucose and serum 
insulin measured at fasting and 30 and 120 min after the oral 
glucose load. A description of assays for measurements for glu-
cose, insulin, and lipids has been published (20, 21) and the as-
says were similar at baseline and at follow-up. LDL-cholesterol was 
calculated by the Friedewald equation if triglycerides were <4.56 
mmol/l (24). Individuals receiving lipid-lowering treatment (of 
3,474 individuals: baseline, n = 28; follow-up, n = 123; combined, 
n = 125) had lipid levels corrected by the statin constants pro-
posed by Wu et al. (25): HDL-cholesterol, 0.059 mmol/l; LDL-
cholesterol, 1.279 mmol/l; total cholesterol, 1.336 mmol/l; and 
triglyceride, 0.207 mmol/l. The participants did not give informa-
tion on the type of lipid lowering medication, but Danish guide-
lines state that statins should be the first-line drug of choice (26). 
Sensitivity analyses were performed by excluding individuals 
influencing levels of triglycerides (8–10), which together 
explain up to 9.3–9.6% of the variance in fasting serum 
triglyceride concentrations estimated from a random sam-
ple of adults from the FINRISK cohort (8) and in the Fram-
ingham Heart study (9).
It is increasingly acknowledged that prevention and treat-
ment of metabolic diseases are not equally efficacious in all 
people and thus the concept called “precision medicine” has 
lately received a lot of attention. In order to fulfill the require-
ment of tailored treatment and prevention, one important 
first step is to understand the pathogenic mechanism of ge-
netic variants and their complex interplay with the environ-
mental factors that each individual is continuously facing.
While many studies have consolidated the effect of ge-
netic  risk  variants  in cross-sectional  studies,  fewer  studies 
have focused on prospective analyses (11–13) and interac-
tions with metabolic and lifestyle factors (14–17). A few 
studies based on genetic risk scores (GRSs) with 32 and 40 
triglyceride-associated SNPs, respectively, have found that a 
higher genetic load associates with increased concentra-
tion of triglycerides over 9 and 10 years of follow-up (12, 
13). Very few interactions with metabolic and lifestyle fac-
tors have been investigated in prospective studies for the 
full  triglyceride  GRS.  One  study  performed  prospective 
age-GRS interaction analyses and found that the effect of 
the triglyceride GRS on levels of triglycerides was stronger 
in younger (age: 45–54 years) participants than in older 
(age: 55–64 years) (12). Another study tested a combined 
LDL-cholesterol, HDL-cholesterol, and triglyceride GRS of 
32 SNPs for a differential effect on lipid levels during one 
year in response to lifestyle or metformin treatment in the 
Diabetes Prevention Program (18). No genetic modulation 
of the triglyceride response was observed in this study for 
the combined lipid GRS.
We and others have reported interactions with triglycer-
ide GRS  in  the  cross-sectional  setting,  including  interac-
tions with BMI and insulin resistance using homeostatic 
model assessment of insulin resistance (HOMA-IR) (14–17, 
19). Taken together these cross-sectional results point to-
ward a bigger effect of the triglyceride GRS on triglycerides 
in obese individuals compared with lean individuals. How-
ever, because obesity and insulin resistance often coincide 
and are associated with lifestyle-related parameters, it is un-
certain which of these factors is more relevant for the inter-
actions observed. Moreover, a recent study has suggested 
that the interaction between triglyceride GRS and BMI is 
stronger in women (17).
The aim of this study was to investigate whether the com-
plex interplay between blood triglyceride levels and insulin 
resistance and obesity could be modified by genetic factors. 
With the present analyses, we sought to investigate interac-
tions  between  a GRS  for  triglyceride  and obesity/insulin 
resistance modeled in a dynamic setting with changes oc-
curring over 5 years.
Using the prospective Inter99 cohort, we specifically 
aimed to evaluate the effect of a triglyceride weighted GRS 
(wGRS) on changes in fasting serum triglyceride levels dur-
ing a 5 year follow-up period and to assess whether the 
effect of the wGRS on changes in triglycerides was modified 
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Statistical analyses
The statistical analyses were performed using the statistical soft-
ware  R,  version  3.2.1  (http://www.r-project.org/).  Individuals 
were included in the analyses only if they had nondiabetic glucose 
values in the fasting condition and 2 h following an OGTT accord-
ing to World Health Organization 1999 criteria (33) both at the 
baseline and the follow-up examination. A total of 504 individuals 
were excluded. Paired t-tests were used to test for differences in 
serum triglyceride from baseline to follow-up. We applied three 
linear regression models to test the effect of the wGRS on 5 year 
changes in serum triglyceride levels: Model 1, a simple model in-
cluding only the wGRS, sex, age, baseline triglyceride, and inter-
vention program of Inter99: 5 year triglyceride = 0 + 1 wGRS + 
2 age + 3 sex + 4 baseline triglyceride + 5 intervention + . 
Model 2, as model 1 and also including baseline BMI, baseline 
HOMA-IR, 5 year BMI, and 5 year HOMA-IR. Model 3, a fully ad-
justed model as model 2 and also including baseline waist circum-
ference, baseline HDL-cholesterol, baseline LDL-cholesterol, 5 
year waist circumference, 5 year HDL-cholesterol, 5 year LDL-
cholesterol, and baseline and 5 year lifestyle scores for smoking 
habits, alcohol intake, diet, and physical activity. Values of serum 
triglyceride, serum total cholesterol, serum HDL-cholesterol, se-
rum LDL-cholesterol, and HOMA-IR were logarithmically trans-
formed to approach a normal distribution. Additive interactions 
between wGRS and changes in metabolic and lifestyle traits were 
tested  by  introducing  interaction  terms  (wGRS  ×  baseline  trait 
value and wGRS × 5 year trait value) in the association model 1: 5 
year triglyceride = 0 + 1 wGRS + 2 age + 3 sex + 4 baseline 
triglyceride + 5 intervention + 6 baseline trait value + 7 5 year 
trait value + (8 wGRS × baseline trait value) + (9 wGRS × 5 year 
trait value) + . Sensitivity analyses were performed by doing in-
verse normal transformation for the levels of serum triglyceride 
values and HOMA-IR to ensure that results were not driven by 
artifacts arising from skewed distributions. A P value was con-
sidered significant if below the Bonferroni corrected threshold of 
P = 0.006 (corrected for eight tests).
RESULTS
Genetic associations with 5 year changes in fasting serum 
triglyceride level
A total of 3,474 individuals had information on the 
wGRS and fasting serum triglyceride levels at baseline and 
follow-up. A description of study participants is shown in 
supplemental Table S1. During the 5 years, these partici-
pants, on average, increased in fasting serum triglyceride 
[5.4% (4.0; 6.7), P = 9.0 × 1015). Furthermore, on average, 
the BMI, total cholesterol, and HDL-cholesterol increased, 
while LDL-cholesterol and HOMA-IR decreased. Descrip-
tions of average changes in the population are shown in 
supplemental Tables S3–S5.
The distribution of the wGRS in the study population is 
shown  in  supplemental Fig.  S1. The wGRS was positively 
associated with changes in triglyceride levels over a 5 year 
period (Table 1). In a model adjusted for age, sex, in-
tervention, and baseline triglycerides, each additional 
weighted risk allele was associated with an increase  in se-
rum triglyceride level of 1.3% (1.0–1.6%), P = 1.0 × 1017 
(n = 3,474) (Table 1), this corresponds to 0.009–0.018 
mmol/l for the interquartile range (IQR) of the distribu-
tion. The association increased in strength and magnitude 
receiving lipid lowering medication (n = 125 in the present analy-
ses). HOMA-IR was calculated as: [fasting plasma glucose (mmol/l) 
× fasting serum insulin (pmol/l)]/135 (27).
Lifestyle measures
Dietary habits, alcohol consumption, physical activity, and 
smoking were  all  estimated  from questionnaire data  and calcu-
lated into discrete score variables. A three-point dietary score was 
derived  from  a  validated  food  frequency  questionnaire.  The 
scores were constructed as: 1, unhealthy; 2, moderately healthy; 
and 3, healthy. A higher dietary score was related to a lower intake 
of saturated fat and a higher intake of vegetables, fruit, and fish 
(28).  The  self-reported  total  intake  of  alcoholic  beverages  per 
week was calculated into units of ethanol (1 unit = 12 g) and di-
vided into a score from 1 to 4; 1, abstinent; 2, less than 14/21 
(women/men)  units  per  week;  3,  more  than  14/21  (women/
men) units per week and less than 35 units per week; and 4, more 
than 35 units per week. The level of physical activity was estimated 
from time spent actively commuting (minutes per week) and time 
spent on  leisure time physical activity (minutes per week) (21). 
Subsequently, a physical activity score from 1 to 4 was created: 1, 
0–113 min/week; 2, 143–225 min/week; 3, 255–340 min/week; 
and 4, 450–720 min/week (29). Smoking habits were divided into 
a  score  from  1  to  4;  1,  habitual/daily  smoker;  2,  occasional 
smoker;  3,  former  smoker;  and  4,  nonsmoker  (30).  From  the 
scores described above, 5 year changes in each lifestyle measure 
were individually defined into three classes as follows: class 1, 
healthier if the 5 year lifestyle score was calculated to be better 
than at baseline; class 2, no change if the 5 year lifestyle score was 
the same as the baseline; or class 3, unhealthier if the 5-year life-
style score was calculated to be worse than the baseline.
SNP selection and genotyping
The SNPs were selected based on Teslovich et al. (9) and Willer 
et al. (10) that have confirmed 40 loci associating with circulating 
fasting levels of triglycerides at genome-wide significance (P < 5 × 
108).  Of  the  identified  triglyceride  risk  variants,  one  variant 
(CTF1 rs11649653) was not present and was not captured by any 
proxies (r2  0.80) on Illumina Cardio-Metabochip or Human 
Exome BeadChip. Hence, we included 39 loci, of which 4 were 
proxies (r2  0.97). Proxy search was performed based on Hap-
Map and 1000 Genomes Pilot 1 data for  linkage disequilibrium 
estimation using SNP annotation proxy search (SNAP; available 
from http://www.broadinstitute.org/mpg/snap/). An overview 
of variants used in the present study is given in supplemental 
Table S2.
Individuals from Inter99 were genotyped using the Cardio-
Metabochip (31) and Human Exome BeadChip on an Illumina 
HiScan system (Illumina, San Diego, CA). Quality control and 
genotype calling have previously been described (14).
GRS
The effect of multiple genetic risk loci was studied by construct-
ing a wGRS as previously described (32). We used reported effect 
sizes (9, 10) for each SNP to weight the contribution of each risk 
allele, which was defined as the allele reported to be associated 
with increased levels of fasting triglyceride. Proxies were weighted 
using the reported effect sizes for lead SNPs, because these reflect 
the same association signal (supplemental Table S2). Analyses 
were performed using the wGRS on a continuous scale. Individu-
als with more than two missing genotypes were excluded (n = 20). 
For individuals with one (n = 73) or two (n = 25) missing geno-
types,  genotypes  were  imputed  by  assessing  the  most  frequent 
genotype in Inter99 for the specific variant. The mean number of 
risk alleles was 38.5 ranging from 24 to 53.
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(0.2; 1.3), P = 0.01 per risk allele, while  it was 1.7% (1.2; 
2.3), P = 2.7 × 109 in the highest quartile of HOMA-IR 
(Fig. 1).
The effect of the wGRS on changes in fasting serum tri-
glycerides also showed an interaction with changes in BMI 
and physical activity Pint < 0.05, but these were not signifi-
cant after correction for multiple testing. No other interac-
tions with changes in waist circumference and changes in 
lifestyle factors were observed (Pint > 0.05) (Table 2).
As it has previously been suggested that the interaction 
of the triglyceride GRS with BMI on serum triglycerides is 
stronger in women (17), we tested our interaction with 
HOMA-IR in men and women separately. In men, the in-
teraction  between  wGRS  and  HOMA-IR  on  changes  in  
serum triglyceride was only borderline significant (Pint = 
0.025), while this interaction was highly significant in 
women (Pint = 2.3 × 10
5).
The wGRS was not associated with changes in HOMA-IR 
in a model adjusted for age, sex, intervention, and baseline 
HOMA-IR (P = 0.46). Sensitivity analyses, excluding indi-
viduals treated with lipid lowering medication, did not 
change the results (data not shown). When analyzing the 
interactions using inverse normal transformation instead 
of logarithmic transformation for the skewed variables, the 
interaction  between  wGRS  and HOMA-IR  on  change  in 
fasting serum triglycerides remained significant (Pint = 6.5 × 
104). Analyses of relevant metabolic factors affecting 
change in HOMA-IR are shown in supplemental Table S7.
DISCUSSION
In the present study, we have performed prospective 
analyses  of  a wGRS  comprising  39  triglyceride-increasing 
variants in the nondiabetic segment of the Danish Inter99 
cohort. We have examined how triglyceride-raising loci 
predict longitudinal changes in fasting serum triglyceride 
levels over 5 years and some of the factors modifying this 
relationship. We found that a wGRS of triglyceride-increas-
ing alleles was associated with increased levels of fasting 
serum triglyceride over 5 years in a middle-aged Danish 
population. Moreover, in this study, we showed that indi-
viduals carrying an increased load of triglyceride-increas-
ing genetic variants have an accentuated effect of this 
unfavorable genetic predisposition when they increase 
when the model was additionally adjusted for baseline and 
5 year BMI and baseline and 5 year HOMA-IR [1.5% (1.2; 
1.8), P = 1.0 × 1027 (n = 3,352)] (Table 1). A fully adjusted 
model, additionally including baseline and 5 year waist cir-
cumference, baseline and 5 year HDL-cholesterol, baseline 
and 5 year LDL-cholesterol, baseline and 5 year alcohol in-
take, baseline and 5  year  smoking habits, baseline and 5 
year physical activity, and baseline and 5 year dietary score, 
resembled the results of model 1 [1.2 (0.9–1.4), P = 1.4 × 
1015 (n = 2,638)] (Table 1). Excluding individuals treated 
with lipid lowering medication produced similar results 
(data not shown).
Interactions
To  explore whether  the  effect  of  the wGRS on  serum 
triglycerides was affected by degree of adiposity, insulin re-
sistance, and lifestyle factors, we tested for potential inter-
actions. Main effect analysis is shown in supplemental 
Table S6. We fitted separate interaction models for the 
changes in adiposity (BMI and waist circumference), 
change in insulin resistance (HOMA-IR), and changes in 
lifestyle  factors  (physical  activity,  smoking  habits,  dietary 
score, and alcohol intake) (Table 2). In a model adjusted 
for age, sex, intervention, and baseline triglyceride, we 
found  an  interaction  between  the  wGRS  and  change  in 
HOMA-IR  in  relation  to 5  year  changes  in  fasting  serum 
triglyceride levels (Pint = 1.5 × 10
6) (Table 2). An increase 
in HOMA-IR accentuated the effect of the wGRS on 5 year 
change in fasting serum triglyceride (Fig. 1). In the lowest 
quartile of HOMA-IR,  the effect of  the wGRS was 0.7% 
TABLE  1.  Associations between the wGRS and changes in serum triglyceride level over 5 year follow-up in the 
Inter99 cohort
Model 1 Model 2 Model 3
Effect of wGRS (95% CI) 1.3% (1.0–1.6) 1.5% (1.2–1.8) 1.2% (0.9–1.4)
Effect in mmol/l IQR 0.009–0.018 0.01–0.02 0.008–0.017
P 1.0 × 1017 1.0 × 1027 1.4 × 1015
n 3,474 3,352 2,638
Data is effect per weighted risk allele given in percent (95% CI) and the mean effect translated into millimoles 
per liter for IQR of the baseline distribution and P values of three different models. Three models were analyzed: 
model 1, a simple model including only the GRS, sex, age, intervention, and baseline triglyceride; model 2, a model 
including GRS, sex, age, intervention, baseline triglyceride, baseline and 5 year BMI, and baseline and 5 year HOMA-
IR; model 3, a fully adjusted model including GRS, sex, age, intervention, baseline triglyceride, baseline and 5 year 
BMI, baseline and 5 year HOMA-IR, baseline and 5 year waist circumference, baseline and 5 year HDL-cholesterol, 
baseline and 5 year LDL-cholesterol, baseline and 5 year smoking habits, baseline and 5 year alcohol intake, baseline 
and 5 year dietary score, and baseline and 5 year physical activity.
TABLE  2.  Interactions between wGRS and changes in adiposity, 
insulin resistance, and lifestyle factors in relation to 5 year changes in 
serum triglyceride levels in the Inter99 cohort
P Interaction n
BMI 0.03 3,473
Waist circumference 0.07 3,474
HOMA-IR 1.5 × 106 3,353
Physical activity 0.03 3,227
Smoking habits 0.20 3,452
Dietary score 0.05 3,339
Alcohol intake 0.96 3,057
Seven separate interaction models were analyzed by introducing 
the interaction terms wGRS × baseline trait and wGRS × 5 year trait into 
model 1 (including only the wGRS, age, sex, intervention, and baseline 
serum triglyceride and the interaction terms).
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that 5 years is not a sufficient follow-up period to observe 
the dynamic interaction. The previously reported interac-
tions with both BMI and insulin resistance may represent 
the same underlying interaction because obese individuals 
are also likely to be insulin resistant. Underlining the com-
plexity, the triglyceride wGRS is reported to associate with 
decreased risk of type 2 diabetes and with lower levels of 
HOMA-IR when adjusting for circulating levels of triglycer-
ides (34, 35).
We found a borderline interaction with changes in physi-
cal activity; i.e., those decreasing their physical activity had 
a  stronger effect of  the wGRS on  triglyceride  levels. This 
suggestive finding could be a potential false-negative find-
ing because of low power in the statistical analyses. Because 
peripheral insulin action is strongly linked to physical activ-
ity level, the change in physical activity may partly be ex-
planatory for the interaction with both BMI and insulin 
resistance observed in this and previous studies. It would be 
of interest to follow-up on this suggestive finding in a larger 
cohort and preferentially with objectively measured physi-
cal activity. Also of notice, it has recently been suggested 
that  the  interaction  between  the  triglyceride  wGRS  and 
BMI is stronger in women (17). In the present study, we 
confirm this observation also for the interaction between 
the wGRS and HOMA-IR.
Our study provides an example that an increase in insu-
lin resistance has a more adverse effect on blood triglycer-
ides for individuals with a specific genetic predisposition to 
increased triglycerides. From a public health perspective, it 
could be anticipated that recommendations about staying 
insulin sensitive, e.g., by doing exercise, would be more 
strongly encouraged or even prescribed to individuals at a 
high genetic risk. Exercise has a well-known effect on im-
proving insulin sensitivity and is a factor that is relatively 
easily modified. Other factors that are suggested to be in-
volved in insulin resistance and which could, in theory, be 
modifiable are adiposity (modified by both diet and exer-
cise), emotional stress, sleep, and the gut microbiome (36–
38). However, at present, genetic studies of complex traits 
their insulin resistance over the same 5 year period of fol-
low-up. In other words, improvement of insulin sensitivity 
attenuates  the  effect  of  the  wGRS  on  levels  of  serum 
triglycerides.
Two previous studies have reported a triglyceride-in-
creasing effect of a wGRS over 9 and 10 years in studies in-
volving 9,328 and 3,495 individuals, respectively (12, 13). 
In the GLACIER study cohort, the reported effect per al-
lele was an increase of 0.02 mmol/l in fasting serum triglyc-
eride over 10 years (13). This per allele effect corresponds 
to the effect we observe in the present study. In raw values, 
individuals  in  the  highest  quintile  (10%)  of  genetic  risk 
had a mean increase of serum triglycerides of 0.061 mmol/l 
over 5 years, while those in the lowest quintile had a mean 
increase of 0.036 mmol/l.
In children, a triglyceride GRS has also been shown to 
have an effect on serum triglyceride level already at 3–6 
years of age, but with a lesser effect than in adulthood (11). 
This stronger effect in adulthood was not observed for 
GRSs  for  serum  levels  of  HDL-cholesterol,  LDL-choles-
terol, and total cholesterol, indicating that the triglyceride 
GRS may be a good candidate for gene-environment inter-
actions in the adults. Therefore, we sought to determine 
whether the genetic predisposition to elevated triglyceride 
levels was modified by changes in adiposity, insulin resis-
tance, and lifestyle factors. We found that changes in insu-
lin resistance (HOMA-IR) modified the effect of the wGRS. 
With increasing insulin resistance over 5 years, the effect of 
the triglyceride wGRS was stronger.
Previous studies of interactions in cross-sectional settings 
have found comparable interactions suggesting a stronger 
association between the wGRS and triglycerides in obese or 
in more insulin-resistant individuals (14–17, 19). In this 
study, we demonstrate that the interaction with HOMA-IR 
is also evident in a prospective setting consolidating the re-
sults from previous studies using cross-sectional data. We 
did not observe an interaction with BMI or waist circumfer-
ence in the prospective setting over 5 years. One explana-
tion may be that adiposity is changing at a slower pace and 
Fig. 1. Visualization of the interaction between the 
wGRS and change in HOMA-IR levels over 5 years. 
The effect of the wGRS on changes in serum triglyc-
eride  levels  is  shown  by  quartiles  of  HOMA-IR 
change. Values of HOMA-IR and serum triglyceride 
were logarithmically transformed before calculating 
the change and the change is thus calculated as the 
proportional (percentage) change relative to base-
line value. The first quartile comprises  individuals 
having 35% lower follow-up HOMA-IR compared 
with  baseline.  The  second  quartile  includes  indi-
viduals having between 8% and 35% lower follow-
up  HOMA-IR.  The  third  quartile  comprises  the 
group of individuals having between 8% lower and 
31% higher follow-up HOMA-IR. The fourth quar-
tile includes the group of individuals having 31% 
higher  follow-up HOMA-IR. Pint denotes the inter-
action P value expressing the interaction between 
wGRS and quartiles of HOMA-IR in model 1 (in-
cluding only  the wGRS,  age,  sex,  and baseline  se-
rum triglyceride).
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In conclusion, in nondiabetic middle-aged people, in-
creased genetic risk is associated with a larger increase in 
fasting serum triglyceride levels during 5 years. The genetic 
risk of increased triglycerides during 5 years of follow-up is 
modified by insulin resistance; i.e., in individuals who be-
come more insulin resistant over 5 years, the triglyceride-
increasing effect of the wGRS is accentuated.
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